Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or
the "Company"), a leading short-stay surgical facility owner and
operator, today announced results for the fourth quarter and full
year ended December 31, 2023.
- Revenue increased 8.0% to $2.74
billion in the full-year 2023 and 4.0% to $735.4 million in the
fourth quarter 2023, when compared to the comparable periods in
2022
- Days adjusted same-facility revenues
increased 11.3% in the full-year 2023 versus 2022
- Days adjusted
same-facility revenues increased 8.1% in the fourth quarter 2023
versus 2022
- Net loss attributable to common
stockholders was $11.9 million for the full-year 2023 and $1.0
million for the fourth quarter 2023
- Adjusted EBITDA increased 15.2% to
$438.1 million in the full-year 2023 versus 2022
- Adjusted EBITDA
increased 17.8% to $142.3 million in the fourth quarter 2023 versus
2022
- Adjusted EBITDA
margins were 16.0% in the full-year 2023 and 19.4% in the fourth
quarter 2023
- Revenue for 2024
expected to be greater than $3.0 billion and Adjusted EBITDA
expected to be greater than $495 million
Wayne DeVeydt, Chairman of the Board of Surgery
Partners, noted, “We are pleased to report another year of
mid-teens growth with our 2023 Adjusted EBITDA exceeding $438
million, representing 15% growth over 2022. The strategic
initiatives the Company implemented in 2023 will further catalyze
our growth engine as we enter into 2024. We are poised to continue
to capitalize on industry trends and remain optimistic about
achieving sustainable mid-teens Adjusted EBITDA growth.”
Eric Evans, Chief Executive Officer, stated, “I am
proud of the Company’s continued consistent and predictable growth
story. Our long-term growth algorithm strategically positions us to
deliver on our commitment of double-digit earnings growth.
Supported by our same-facility revenue growth of greater than 11%
in 2023, we are reporting top-line growth and margin expansion,
consistent with our expectations, and reflecting the positive
trajectory that we have experienced all year. This strong growth
gives us significant momentum as we enter 2024.”
Dave Doherty, Chief Financial Officer, commented,
“We are pleased to deliver these fourth quarter and full year
results, which reflects our disciplined management approach, strong
underlying business fundamentals and the benefits of our multi-year
growth investments. With the execution of the December 2023 credit
facility refinancing, we have effectively shifted any material debt
maturities to the end of the decade while reducing interest costs.
Based on new term loan definitions which both better reflect market
practice and match assets and liabilities, the ratio of total net
debt to EBITDA is now 3.5x. As we entered 2024, our liquidity
position is near $900 million, which enhances our confidence in our
ability to continue to fund accretive M&A. With the momentum of
these results, we are reaffirming our 2024 Adjusted EBITDA guidance
to be greater than $495 million and setting 2024 revenue guidance
to be greater than $3.0 billion.”
Fourth Quarter
2023 Results
Revenue for the fourth quarter of 2023 increased
4.0% to $735.4 million from $707.1 million for the fourth quarter
of 2022. Days adjusted same-facility revenues for the fourth
quarter of 2023 increased 8.1% from the same period last year, with
a 6.7% increase in revenue per case and a 1.4% increase in
same-facility cases. For the fourth quarter of 2023, the Company’s
Adjusted EBITDA was $142.3 million, compared to $120.8 million for
the same period last year.
Full Year 2023
Results
Revenue for 2023 increased 8.0% to $2,743.3 million
from $2,539.3 million in 2022. Days adjusted same-facility revenues
for the year ended 2023 increased 11.3% from the prior year, with a
7.1% increase in revenue per case and a 3.9% increase in
same-facility cases. For the full year 2023, the Company’s Adjusted
EBITDA was $438.1 million, compared to $380.2 million in 2022.
Liquidity
Surgery Partners had cash and cash equivalents of
$195.9 million and $694.3 million of borrowing capacity under its
revolving credit facility at December 31, 2023. Cash flows
from operating activities was $62.6 million for the fourth quarter
2023, compared to $7.2 million for the same period in 2022. Free
Cash Flow, defined as operating cash flows less distributions to
non-controlling interests and less maintenance-related capital
expenditures, was $18.5 million for the fourth quarter of 2023.
Operating cash flows were $293.8 million for 2023,
compared to $158.8 million for 2022. The increase in operating cash
flows was driven primarily by reductions of $49.1 million of
interest paid, net of interest income received, and
$18.8 million of payments under the tax receivable agreement,
operating cash flows in 2022 that did not repeat in the current
year, including repayments of approximately $57.2 million of
Medicare advanced payments provided through the CARES Act,
partially offset by the receipt of stockholder litigation proceeds
of $32.8 million, an increase in net income and the timing of
routine transactions involving working capital and accrued payroll
and benefits. Free Cash Flow was $109.9 million for full year
2023.
The Company’s ratio of total net debt to EBITDA, as
calculated under the Company’s credit agreement, was 3.5x at the
end of 2023.
2024 Outlook
The Company projects 2024 revenues to be greater
than $3.0 billion, projects 2024 Adjusted EBITDA to be greater than
$495 million.
Conference Call Information
Surgery Partners will hold a conference call today,
February 26, 2024 at 8:30 a.m. (Eastern Time). The conference
call can be accessed live over the phone by dialing 1-877-451-6152,
or for international callers, 1-201-389-0879. A replay will be
available three hours after the call and can be accessed by dialing
1-844-512-2921, or for international callers, 1-412-317-6671. The
passcode for the live call and the replay is 13744429. The replay
will be available until March 11, 2024.
Interested investors and other parties may also
listen to a simultaneous webcast of the conference call by logging
onto the Investor Relations section of the Company's website at
www.surgerypartners.com. The replay will also be available on this
same website for a limited time following the call.
To learn more about Surgery Partners, please visit
the Company's website at www.surgerypartners.com. Surgery Partners
uses its website as a channel of distribution for material Company
information. Financial and other material information regarding
Surgery Partners is routinely posted on the Company's website and
is readily accessible.
About Surgery Partners
Headquartered in Brentwood, Tennessee, Surgery
Partners is a leading healthcare services company with a
differentiated outpatient delivery model focused on providing high
quality, cost effective solutions for surgical and related
ancillary care in support of both patients and physicians. Founded
in 2004, Surgery Partners is one of the largest and fastest growing
surgical services businesses in the country, with more than 180
locations in 33 states, including ambulatory surgery centers,
surgical hospitals, multi-specialty physician practices and urgent
care facilities. For additional information, visit
www.surgerypartners.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including those regarding growth, our anticipated
operating results for future periods and other similar statements.
These statements can be identified by the use of words such as
"believes," "anticipates," "expects," "intends," "plans,"
"continues," "estimates," "predicts," "projects," "forecasts,"
"may," "could," and similar expressions. All forward-looking
statements are based on current expectations and beliefs as of the
date of this release and are subject to risks, uncertainties and
other factors that may cause actual results to differ materially
from the expectations discussed in, or implied by, the
forward-looking statements. Many of these factors are beyond our
ability to control or predict including, without limitation,
reductions in payments from government health care programs and
private insurance payors, such as health maintenance organizations,
preferred provider organizations, and other managed care
organizations and employers; our ability to contract with private
insurance payors; changes in our payor mix or surgical case mix;
failure to maintain or develop relationships with physicians on
beneficial or favorable terms, or at all; the impact of payor
controls designed to reduce the number of surgical procedures; our
efforts to integrate operations of acquired businesses and surgical
facilities, attract new physician partners, or acquire additional
surgical facilities; supply chain issues, including shortages or
quality control issues with surgery-related products, equipment and
medical supplies; competition for physicians, nurses, strategic
relationships, acquisitions and managed care contracts; our ability
to attract and retain qualified health care professionals; our
ability to enforce non-compete restrictions against our physicians;
our ability to manage material liabilities whether known or unknown
incurred as a result of acquiring surgical facilities; the impact
of future legislation and other health care regulatory reform
actions, and the effect of that legislation and other regulatory
actions on our business; our ability to comply with current health
care laws and regulations; the outcome of legal and regulatory
proceedings that have been or may be brought against us; the impact
of cybersecurity attacks or intrusions, changes in the regulatory,
economic and other conditions of the states where our surgical
facilities are located; our indebtedness; the social and economic
impact of a pandemic, epidemic or outbreak of a contagious disease,
such as COVID-19, on our business; and the risks and uncertainties
identified and discussed from time to time in the Company’s reports
filed with the SEC, including in Item 1A under the heading "Risk
Factors" in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2022 and Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2023, June 30, 2023 and September 30,
2023. Except as required by law, the Company undertakes no
obligation to revise or update publicly any forward-looking
statements to reflect events or circumstances after the date of
this report, or to reflect the occurrence of unanticipated events
or circumstances.
Use of Non-GAAP Financial
Measures
In addition to the results prepared in accordance
with generally accepted accounting principles in the United
States ("GAAP") provided throughout this press release,
Surgery Partners has presented the following non-GAAP financial
measures: Adjusted net income (loss) attributable to common
stockholders, Adjusted net income (loss) per share attributable to
common stockholders, Adjusted EBITDA, Adjusted EBITDA excluding
grant funds, Adjusted EBITDA related to unconsolidated affiliates,
and Free Cash Flow, which exclude various items detailed in the
"Reconciliation of Non-GAAP Financial Measures" below.
These non-GAAP financial measures are not intended
to replace financial performance measures determined in accordance
with GAAP. Rather, they are presented as supplemental measures of
the Company's performance that management believes may enhance the
evaluation of the Company's ongoing operating results. These
non-GAAP financial measures are not presented in accordance with
GAAP, and the Company’s computation of these non-GAAP financial
measures may vary from similar measures used by other companies.
These measures have limitations as an analytical tool and should
not be considered in isolation or as a substitute or alternative to
revenue, net income or loss, operating income or loss, cash flows
from operating activities, total indebtedness or any other measures
of operating performance, liquidity or indebtedness derived in
accordance with GAAP.
SURGERY PARTNERS, INC. SELECTED
CONSOLIDATED FINANCIAL DATA(Dollars in millions,
except per share amounts, shares in
thousands)(Unaudited) |
|
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ |
735.4 |
|
|
$ |
707.1 |
|
|
$ |
2,743.3 |
|
|
$ |
2,539.3 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Salaries and benefits |
|
|
201.4 |
|
|
|
200.1 |
|
|
|
793.8 |
|
|
|
746.4 |
|
Supplies |
|
|
195.2 |
|
|
|
191.4 |
|
|
|
745.0 |
|
|
|
709.7 |
|
Professional and medical fees |
|
|
76.9 |
|
|
|
70.8 |
|
|
|
296.8 |
|
|
|
269.2 |
|
Lease expense |
|
|
20.6 |
|
|
|
20.6 |
|
|
|
84.9 |
|
|
|
82.4 |
|
Other operating expenses |
|
|
47.7 |
|
|
|
39.9 |
|
|
|
175.3 |
|
|
|
156.7 |
|
Cost of revenues |
|
|
541.8 |
|
|
|
522.8 |
|
|
|
2,095.8 |
|
|
|
1,964.4 |
|
General and administrative expenses |
|
|
20.9 |
|
|
|
28.7 |
|
|
|
120.9 |
|
|
|
102.2 |
|
Depreciation and amortization |
|
|
31.1 |
|
|
|
29.6 |
|
|
|
118.1 |
|
|
|
114.8 |
|
Transaction and integration costs |
|
|
24.4 |
|
|
|
19.7 |
|
|
|
61.7 |
|
|
|
47.5 |
|
Grant funds |
|
|
— |
|
|
|
(0.6 |
) |
|
|
(1.1 |
) |
|
|
(2.4 |
) |
Net loss on disposals, consolidations and deconsolidations |
|
|
6.9 |
|
|
|
7.9 |
|
|
|
14.4 |
|
|
|
11.1 |
|
Equity in earnings of unconsolidated affiliates |
|
|
(4.8 |
) |
|
|
(4.4 |
) |
|
|
(14.2 |
) |
|
|
(12.5 |
) |
Litigation settlement |
|
|
2.5 |
|
|
|
3.5 |
|
|
|
10.6 |
|
|
|
(29.3 |
) |
Loss on debt extinguishment |
|
|
15.5 |
|
|
|
14.9 |
|
|
|
15.5 |
|
|
|
14.9 |
|
Other income, net |
|
|
(4.3 |
) |
|
|
(9.2 |
) |
|
|
(6.4 |
) |
|
|
(16.6 |
) |
|
|
|
634.0 |
|
|
|
612.9 |
|
|
|
2,415.3 |
|
|
|
2,194.1 |
|
Operating income |
|
|
101.4 |
|
|
|
94.2 |
|
|
|
328.0 |
|
|
|
345.2 |
|
Interest expense, net |
|
|
(48.7 |
) |
|
|
(61.0 |
) |
|
|
(193.0 |
) |
|
|
(234.9 |
) |
Income before income taxes |
|
|
52.7 |
|
|
|
33.2 |
|
|
|
135.0 |
|
|
|
110.3 |
|
Income tax (expense) benefit |
|
|
(6.0 |
) |
|
|
(9.9 |
) |
|
|
0.3 |
|
|
|
(23.3 |
) |
Net income |
|
|
46.7 |
|
|
|
23.3 |
|
|
|
135.3 |
|
|
|
87.0 |
|
Less: Net income attributable to non-controlling interests |
|
|
(47.7 |
) |
|
|
(46.7 |
) |
|
|
(147.2 |
) |
|
|
(141.6 |
) |
Net loss attributable to Surgery Partners, Inc. |
|
$ |
(1.0 |
) |
|
$ |
(23.4 |
) |
|
$ |
(11.9 |
) |
|
$ |
(54.6 |
) |
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders |
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.01 |
) |
|
$ |
(0.23 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.59 |
) |
Diluted(1) |
|
$ |
(0.01 |
) |
|
$ |
(0.23 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.59 |
) |
Weighted average common shares outstanding |
|
|
|
|
|
|
|
|
Basic |
|
|
125,774 |
|
|
|
101,888 |
|
|
|
125,613 |
|
|
|
91,952 |
|
Diluted(1) |
|
|
125,774 |
|
|
|
101,888 |
|
|
|
125,613 |
|
|
|
91,952 |
|
(1) |
The impact of
potentially dilutive securities for all periods were not considered
because the effect would be anti-dilutive. |
SURGERY PARTNERS, INC. Selected Financial
and Operating Data(Dollars in millions, except per
case and per share
amounts)(Unaudited) |
|
|
|
December 31,2023 |
|
December 31,2022 |
|
|
|
|
|
Balance Sheet Data (at period end): |
|
|
|
|
Cash and cash equivalents |
|
$ |
195.9 |
|
$ |
282.9 |
Total current assets |
|
|
895.0 |
|
|
921.0 |
Total assets |
|
|
6,876.7 |
|
|
6,682.1 |
|
|
|
|
|
Current maturities of long-term debt |
|
|
73.3 |
|
|
62.8 |
Total current liabilities |
|
|
523.0 |
|
|
493.4 |
Long-term debt, less current maturities |
|
|
2,701.8 |
|
|
2,559.0 |
Total liabilities |
|
|
3,514.8 |
|
|
3,399.2 |
|
|
|
|
|
Non-controlling interests—redeemable |
|
|
327.4 |
|
|
342.0 |
|
|
|
|
|
Total Surgery Partners, Inc. stockholders' equity |
|
|
1,987.2 |
|
|
1,998.2 |
Non-controlling interests—non-redeemable |
|
|
1,047.3 |
|
|
942.7 |
Total stockholders' equity |
|
|
3,034.5 |
|
|
2,940.9 |
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Cash Flow Data: |
|
|
|
|
|
|
|
|
Net cash provided by (used in): |
|
|
|
|
|
|
|
|
Operating activities |
|
$ |
62.6 |
|
|
$ |
7.2 |
|
|
$ |
293.8 |
|
|
$ |
158.8 |
|
Investing activities |
|
|
(58.1 |
) |
|
|
(72.2 |
) |
|
|
(225.6 |
) |
|
|
(307.9 |
) |
Purchases of property and equipment |
|
|
(19.8 |
) |
|
|
(22.7 |
) |
|
|
(88.8 |
) |
|
|
(80.6 |
) |
Payments for acquisitions, net of cash acquired |
|
|
(31.2 |
) |
|
|
(63.8 |
) |
|
|
(80.0 |
) |
|
|
(146.4 |
) |
Purchases of equity investments |
|
|
(0.1 |
) |
|
|
— |
|
|
|
(50.3 |
) |
|
|
(95.1 |
) |
Financing activities |
|
|
(44.6 |
) |
|
|
193.1 |
|
|
|
(155.2 |
) |
|
|
42.1 |
|
Distributions to non-controlling interest holders |
|
|
(35.1 |
) |
|
|
(36.3 |
) |
|
|
(146.1 |
) |
|
|
(146.8 |
) |
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Other Data: |
|
|
|
|
|
|
|
|
Number of surgical facilities as of the end of period |
|
|
162 |
|
|
|
146 |
|
|
|
162 |
|
|
|
146 |
|
Number of consolidated surgical facilities as of the end of
period |
|
|
123 |
|
|
|
118 |
|
|
|
123 |
|
|
|
118 |
|
|
|
|
|
|
|
|
|
|
Cases |
|
|
153,193 |
|
|
|
155,644 |
|
|
|
605,846 |
|
|
|
594,232 |
|
Revenue per case |
|
$ |
4,800 |
|
|
$ |
4,543 |
|
|
$ |
4,528 |
|
|
$ |
4,273 |
|
Adjusted EBITDA(1) |
|
$ |
142.3 |
|
|
$ |
120.8 |
|
|
$ |
438.1 |
|
|
$ |
380.2 |
|
Adjusted EBITDA excluding grant funds(1) |
|
$ |
142.3 |
|
|
$ |
120.5 |
|
|
$ |
437.0 |
|
|
$ |
378.5 |
|
Adjusted EBITDA margin(2) |
|
|
19.4 |
% |
|
|
17.1 |
% |
|
|
16.0 |
% |
|
|
15.0 |
% |
Adjusted EBITDA excluding grant funds margin(3) |
|
|
19.4 |
% |
|
|
17.0 |
% |
|
|
15.9 |
% |
|
|
14.9 |
% |
Adjusted net gain per share attributable to common stockholders -
Basic(1) |
|
$ |
0.45 |
|
|
$ |
0.28 |
|
|
$ |
1.01 |
|
|
$ |
0.17 |
|
Adjusted net gain per share attributable to common stockholders -
Diluted(1) |
|
$ |
0.44 |
|
|
$ |
0.27 |
|
|
$ |
1.00 |
|
|
$ |
0.16 |
|
Free Cash Flow(1) |
|
$ |
18.5 |
|
|
N/A |
|
$ |
109.9 |
|
|
N/A |
(1) |
A reconciliation of these non-GAAP financial measures appears
below. |
(2) |
Defined as Adjusted EBITDA as
a % of Revenues. |
(3) |
Defined as Adjusted EBITDA
excluding grant funds as a % of Revenues. |
SURGERY PARTNERS, INC. Supplemental
Information(Dollars in millions, except per case
amounts)(Unaudited) |
|
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
Same-facility
Information(1): |
|
|
|
|
|
|
|
|
Cases |
|
|
171,593 |
|
|
|
169,289 |
|
|
629,151 |
|
|
|
607,742 |
Case growth |
|
|
1.4 |
% |
|
N/A |
|
|
3.5 |
% |
|
N/A |
Revenue per case |
|
$ |
4,611 |
|
|
$ |
4,323 |
|
$ |
4,310 |
|
|
$ |
4,025 |
Revenue per case growth |
|
|
6.7 |
% |
|
N/A |
|
|
7.1 |
% |
|
N/A |
Number of work days in the period |
|
|
61 |
|
|
|
61 |
|
|
252 |
|
|
|
253 |
Case growth (days adjusted) |
|
|
1.4 |
% |
|
N/A |
|
|
3.9 |
% |
|
N/A |
Revenue growth (days adjusted) |
|
|
8.1 |
% |
|
N/A |
|
|
11.3 |
% |
|
N/A |
(1) |
Same-facility
information includes cases and revenues from our consolidated and
non-consolidated surgical facilities (excluding facilities acquired
in new markets or divested during the current and prior
periods). |
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
|
|
|
|
|
|
|
|
Segment Revenues: |
|
|
|
|
|
|
|
|
Surgical facility services |
|
$ |
719.3 |
|
$ |
689.8 |
|
$ |
2,675.8 |
|
$ |
2,470.4 |
Ancillary services |
|
|
16.1 |
|
|
17.3 |
|
|
67.5 |
|
|
68.9 |
Total revenues |
|
$ |
735.4 |
|
$ |
707.1 |
|
$ |
2,743.3 |
|
$ |
2,539.3 |
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA: |
|
|
|
|
|
|
|
|
Surgical Facility Services |
|
$ |
159.9 |
|
|
$ |
153.7 |
|
|
$ |
544.0 |
|
|
$ |
473.6 |
|
Ancillary Services |
|
|
(1.2 |
) |
|
|
(0.1 |
) |
|
|
(3.9 |
) |
|
|
(2.3 |
) |
All other |
|
|
(16.4 |
) |
|
|
(32.8 |
) |
|
|
(102.0 |
) |
|
|
(91.1 |
) |
Total Adjusted EBITDA |
|
$ |
142.3 |
|
|
$ |
120.8 |
|
|
$ |
438.1 |
|
|
$ |
380.2 |
|
SURGERY PARTNERS, INC.Reconciliation of
Non-GAAP Financial Measures(Dollars in millions,
except per share amounts, shares in
thousands)(Unaudited) |
The following table reconciles Adjusted EBITDA to
income before income taxes in the reported consolidated financial
information, the most directly comparable GAAP financial
measure:
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
$ |
52.7 |
|
|
$ |
33.2 |
|
|
$ |
135.0 |
|
|
$ |
110.3 |
|
|
|
|
|
|
|
|
|
|
Net income attributable to non-controlling interests |
|
|
(47.7 |
) |
|
|
(46.7 |
) |
|
|
(147.2 |
) |
|
|
(141.6 |
) |
Interest expense, net |
|
|
48.7 |
|
|
|
61.0 |
|
|
|
193.0 |
|
|
|
234.9 |
|
Depreciation and amortization |
|
|
31.1 |
|
|
|
29.6 |
|
|
|
118.1 |
|
|
|
114.8 |
|
Equity-based compensation expense |
|
|
4.5 |
|
|
|
5.4 |
|
|
|
17.7 |
|
|
|
18.4 |
|
Transaction, integration and acquisition costs(1) |
|
|
26.1 |
|
|
|
20.2 |
|
|
|
64.9 |
|
|
|
48.6 |
|
Net loss on disposals, consolidations and deconsolidations |
|
|
6.9 |
|
|
|
7.9 |
|
|
|
14.4 |
|
|
|
11.1 |
|
Litigation settlements and regulatory change impact(2) |
|
|
3.6 |
|
|
|
3.0 |
|
|
|
17.5 |
|
|
|
(24.7 |
) |
Loss on debt extinguishment |
|
|
15.5 |
|
|
|
14.9 |
|
|
|
15.5 |
|
|
|
14.9 |
|
Undesignated derivative activity(3) |
|
|
— |
|
|
|
(8.1 |
) |
|
|
0.6 |
|
|
|
(8.0 |
) |
Other(4) |
|
|
0.9 |
|
|
|
0.4 |
|
|
|
8.6 |
|
|
|
1.5 |
|
Adjusted EBITDA(5) |
|
$ |
142.3 |
|
|
$ |
120.8 |
|
|
$ |
438.1 |
|
|
$ |
380.2 |
|
Less: Impact of grant funds(6) |
|
|
— |
|
|
|
(0.3 |
) |
|
|
(1.1 |
) |
|
|
(1.7 |
) |
Adjusted EBITDA excluding grant funds |
|
$ |
142.3 |
|
|
$ |
120.5 |
|
|
$ |
437.0 |
|
|
$ |
378.5 |
|
(1) |
This amount includes transaction and integration costs of $24.4
million and $19.7 million for the three months ended December 31,
2023 and 2022, respectively. This amount further includes start-up
costs related to de novo surgical facilities of $1.7 million and
$0.5 million for the three months ended December 31, 2023 and 2022,
respectively.This amount includes transaction and integration costs
of $61.7 million and $47.5 million for the years ended December 31,
2023 and 2022, respectively. This amount further includes start-up
costs related to de novo surgical facilities of $3.2 million and
$1.1 million for the years ended December 31, 2023 and 2022,
respectively. |
(2) |
This amount includes litigation settlement losses of $2.5 million
and $3.5 million for the three months ended December 31, 2023 and
2022, respectively. This amount also includes other litigation
costs of $1.1 million and income of $0.5 million for the three
months ended December 31, 2023 and 2022, respectively.This amount
includes a litigation settlements loss of $10.6 million and a net
gain of $29.3 million for the years ended December 31, 2023 and
2022, respectively. This amount also includes other litigation
costs of $2.5 million and $4.6 million for the years ended December
31, 2023 and 2022, respectively. Additionally, the year ended
December 31, 2023, includes $4.4 million related to the impact
of recent changes in Florida law regarding the use of letters of
protection. |
(3) |
This amount includes the reclassification of $7.5 million of
unrealized gains out of accumulated other comprehensive income into
income related to the de-designation of a portion of one of the
Company's interest rate caps for the three months ended December
31, 2022. This amount further includes fair value changes of
undesignated derivatives for the three months ended December 31,
2022.This amount includes the reclassification of $7.5 million
of unrealized gains out of accumulated other comprehensive income
into income related to the de-designation of a portion of one of
the Company's interest rate caps for the year ended December 31,
2022. This amount further includes fair value changes of
undesignated derivatives for the years ended December 31, 2023 and
2022. |
(4) |
This amount includes estimates for the net impact of the May 2023
cyber event for the three months ended December 31, 2023. For the
three months ended December 31, 2022, this amount reflects losses
incurred, net of insurance proceeds received at certain surgical
facilities that were closed following Hurricane Ian in September
2022.This amount includes estimates for the net impact of the May
2023 cyber event and losses from a divested business for the year
ended December 31, 2023. For the year ended December 31, 2022, this
amount reflects losses incurred, net of insurance proceeds received
at certain surgical facilities that were closed following Hurricane
Ian in September 2022. |
(5) |
We use Adjusted EBITDA as a
measure of financial performance. Adjusted EBITDA is a key measure
used by management to assess operating performance, make business
decisions and allocate resources. Non-controlling interests
represent the interests of third parties, such as physicians, and
in some cases, healthcare systems that own an interest in surgical
facilities that we consolidate for financial reporting purposes. We
believe that it is helpful to investors to present Adjusted EBITDA
as defined above because it excludes the portion of net income
attributable to these third-party interests and clarifies for
investors our portion of Adjusted EBITDA generated by our surgical
facilities and other operations. Adjusted EBITDA is not a
measurement of financial performance under GAAP, and should not be
considered in isolation or as a substitute for net income,
operating income or any other measure calculated in accordance with
GAAP. The items excluded from Adjusted EBITDA are significant
components in understanding and evaluating our financial
performance. We believe such adjustments are appropriate, as the
magnitude and frequency of such items can vary significantly and
are not related to the assessment of normal operating performance.
Our calculation of Adjusted EBITDA may not be comparable to
similarly titled measures reported by other companies. |
(6) |
Represents the impact of grant
funds recognized, net of amounts attributable to non-controlling
interests. |
|
|
The following table provides supplemental
information for Adjusted EBITDA related to unconsolidated
affiliates:
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Adjusted EBITDA related to unconsolidated
affiliates: |
|
|
|
|
|
|
|
Management fee revenues(1)(2) |
$ |
7.0 |
|
$ |
5.3 |
|
$ |
23.4 |
|
$ |
17.5 |
Equity in earnings of unconsolidated affiliates(2) |
|
4.8 |
|
|
4.4 |
|
|
14.2 |
|
|
12.5 |
Plus: |
|
|
|
|
|
|
|
Start-up costs related to unconsolidated de novo surgical
facilities(3) |
|
0.8 |
|
|
0.5 |
|
|
2.1 |
|
|
1.1 |
Adjusted EBITDA related to unconsolidated affiliates |
$ |
12.6 |
|
$ |
10.2 |
|
$ |
39.7 |
|
$ |
31.1 |
(1) |
Includes management and administrative service fees derived from
the non-consolidated facilities that the Company accounts for under
the equity method and management of surgical facilities in which it
does not own an interest. Management fee revenues are included in
Revenues on the Consolidated Statements of Operations. |
(2) |
Included as a component of income
before income taxes in the Adjusted EBITDA reconciliation table
above. |
(3) |
Start-up costs related to de novo
surgical facilities are included in Transaction, integration and
acquisition costs in the Adjusted EBITDA reconciliation table
above. |
|
|
The following table reconciles Free Cash Flow to
net cash provided by operating activities in the reported condensed
consolidated financial information, the most directly comparable
GAAP financial measure:
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
2023 |
|
|
|
2023 |
|
|
|
|
|
Net cash provided by operating activities |
|
62.6 |
|
|
|
293.8 |
|
|
|
|
|
Less: Maintenance capital expenditures |
|
(9.0 |
) |
|
|
(37.8 |
) |
Less: Distributions to non-controlling interest holders |
|
(35.1 |
) |
|
|
(146.1 |
) |
Free Cash Flow(1) |
$ |
18.5 |
|
|
$ |
109.9 |
|
|
|
|
|
Growth capital expenditures |
|
(10.8 |
) |
|
|
(51.0 |
) |
Maintenance capital expenditures |
|
(9.0 |
) |
|
|
(37.8 |
) |
Purchases of property and equipment |
$ |
(19.8 |
) |
|
$ |
(88.8 |
) |
(1) |
Free Cash Flow is defined as cash flow provided by operating
activities, less distributions to non-controlling interest holders
and less maintenance capital expenditures, which are capital
expenditures primarily to maintain our existing facilities. We use
the non-GAAP measure of Free Cash Flow as a measure of liquidity to
determine amounts we can reinvest in our core businesses, such as
amounts available to make acquisitions and invest in growth
projects. In order to provide a meaningful basis for comparison, we
are providing information with respect to our Free Cash Flow for
the three months and year ended December 31, 2023, reconciled to
net cash provided by operating activities, which we believe to be
the most directly comparable measure under GAAP. We are not
presenting the comparative prior year period since we did not track
capital expenditures in this manner prior to the current fiscal
year. Our calculation of Free Cash Flow may not be comparable to
similarly titled measures reported by other companies. |
|
|
From time to time, the Company incurs certain
non-recurring gains or losses that are normally non-operational in
nature and that it does not consider relevant in assessing its
ongoing operating performance. When significant, Surgery Partners’
management and its Board of Directors typically exclude these gains
or losses when evaluating the Company’s operating performance and
in certain instances when evaluating performance for incentive
compensation purposes. Additionally, management believes that
certain investors and equity analysts exclude these or similar
items when evaluating the Company’s current or future operating
performance and in making informed investment decisions regarding
the Company. Accordingly, the Company provides adjusted net gain
attributable to common stockholders and adjusted net gain per share
attributable to common stockholders as supplements to the
comparable GAAP financial measures. Adjusted net gain attributable
to common stockholders and adjusted net gain per share attributable
to common stockholders should not be considered measures of
financial performance under GAAP, and the items excluded from such
measures are significant components in understanding and assessing
financial performance. These measures should not be considered in
isolation or as an alternative to the comparable GAAP measures as
presented in the consolidated financial statements.
The following table reconciles net income as
reflected in the consolidated statements of operations to adjusted
net gain attributable to common stockholders used to calculate
adjusted net gain per share attributable to common
stockholders:
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Consolidated Statements of Operations Data: |
|
|
|
|
|
|
|
Net Income |
$ |
46.7 |
|
|
$ |
23.3 |
|
|
$ |
135.3 |
|
|
$ |
87.0 |
|
Plus (minus): |
|
|
|
|
|
|
|
Net income attributable to non-controlling interests |
|
(47.7 |
) |
|
|
(46.7 |
) |
|
|
(147.2 |
) |
|
|
(141.6 |
) |
Equity-based compensation expense |
|
4.5 |
|
|
|
5.4 |
|
|
|
17.7 |
|
|
|
18.4 |
|
Transaction, integration and acquisition costs |
|
26.1 |
|
|
|
20.2 |
|
|
|
64.9 |
|
|
|
48.6 |
|
Net loss on disposals, consolidations and deconsolidations |
|
6.9 |
|
|
|
7.9 |
|
|
|
14.4 |
|
|
|
11.1 |
|
Litigation settlements and regulatory change impact |
|
3.6 |
|
|
|
3.0 |
|
|
|
17.5 |
|
|
|
(24.7 |
) |
Loss on debt extinguishment |
|
15.5 |
|
|
|
14.9 |
|
|
|
15.5 |
|
|
|
14.9 |
|
Other |
|
0.9 |
|
|
|
0.4 |
|
|
|
8.6 |
|
|
|
1.5 |
|
Adjusted net gain attributable to common stockholders |
$ |
56.5 |
|
|
$ |
28.4 |
|
|
$ |
126.7 |
|
|
$ |
15.2 |
|
|
|
|
|
|
|
|
|
Adjusted net gain per share attributable to common
stockholders |
|
|
|
|
|
|
|
Basic |
$ |
0.45 |
|
|
$ |
0.28 |
|
|
$ |
1.01 |
|
|
$ |
0.17 |
|
Diluted |
$ |
0.44 |
|
|
$ |
0.27 |
|
|
$ |
1.00 |
|
|
$ |
0.16 |
|
Weighted average common shares outstanding |
|
|
|
|
|
|
|
Basic |
|
125,774 |
|
|
|
101,888 |
|
|
|
125,613 |
|
|
|
91,952 |
|
Diluted |
|
127,089 |
|
|
|
103,639 |
|
|
|
127,122 |
|
|
|
94,090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contact
Dave Doherty, Chief Financial OfficerSurgery
Partners, Inc. (615) 234-8940 IR@SurgeryPartners.com
Surgery Partners (NASDAQ:SGRY)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Surgery Partners (NASDAQ:SGRY)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024